ProCE Banner Activity

DESTINY-Lung02: Interim Results With Trastuzumab Deruxtecan (T-DXd) in Patients With Previously Treated HER2-Mutated Metastatic NSCLC

Slideset Download
Conference Coverage
Interim analyses from the phase II DESTINY-Lung02 trial showed clinically meaningful responses and no new safety concerns with T-DXd 5.4 mg/kg in patients with HER2-mutant NSCLC who had received at least 1 previous line of therapy.

Released: September 26, 2022

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp